Prognostic factors in previously treated non-small cell lung cancer patients with and without a positive response to the subsequent treatment with gefitinib

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Hiroshi WatayaYukito Ichinose


Gefitinib, an epidermal growth factor receptor tyrosine kinase inhibitor, has been reported to have a certain anti-tumor effect in previously treated patients with non-small cell lung cancer (NSCLC). However, the prognostic factors in those patients with and without a positive response to gefitinib treatment remain unclear. A retrospective chart review was performed in 131 advanced NSCLC patients who received 250 mg of gefitinib as either a second-line or even later stage treatment from July 2002 to December 2005. The clinical factors including age, gender, performance status (PS), stage, histology, the number of prior types of chemotherapy, and the response to first-line chemotherapy were analyzed. One and 38 patients experienced a complete and partial response, respectively, to gefitinib treatment with an overall response rate of 30%. The median survival time (MST) of all patients receiving gefitinib treatment was 10 months while the MST was 28 months in the 39 gefitinib responders and 6 months in the 92 non-responders. Among the 39 gefitinib responders, the predominant prognostic factor was found to be the effectiveness of the first-line chemotherapy. The MST of the 20 patients with a response to the first-line chemotherapy ...Continue Reading


Jul 31, 2004·Science·Raffaella SordellaJeffrey Settleman
Aug 27, 2004·Proceedings of the National Academy of Sciences of the United States of America·William PaoHarold Varmus
Oct 12, 2004·Lung Cancer : Journal of the International Association for the Study of Lung Cancer·Hiroyasu KanedaMasahiro Fukuoka
Mar 2, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Tetsuya MitsudomiYasushi Yatabe
Jul 15, 2005·The New England Journal of Medicine·Ming-Sound TsaoFrances A Shepherd
Aug 24, 2005·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Miguel TaronTeresa Moran
Oct 6, 2005·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Daphne W BellDaniel A Haber
Jun 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Masahiko AndoMasahiro Fukuoka
Sep 7, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Maria Q BaggstromMark A Socinski

❮ Previous
Next ❯


Aug 6, 2011·Japanese Journal of Clinical Oncology·Atsushi OsoegawaYukito Ichinose
Aug 9, 2015·Clinical Oncology : a Journal of the Royal College of Radiologists·P K JulkaN Manoharan
Apr 1, 2014·Revue des maladies respiratoires·F Chermiti Ben AbdallahA Ben Kheder
Jul 18, 2012·Asian Pacific Journal of Cancer Prevention : APJCP·Ali InalAbdurrahman Isikdogan
Feb 12, 2010·Current Opinion in Oncology

❮ Previous
Next ❯

Related Concepts

Trending Feeds


Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.


Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.


Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.

Related Papers

Lung Cancer : Journal of the International Association for the Study of Lung Cancer
Tatsuro OkamotoYukito Ichinose
The Annals of Thoracic Surgery
K SugioK Sugimachi
Cancer radiothérapie : journal de la Société française de radiothérapie oncologique
C ChargariN Magné
© 2021 Meta ULC. All rights reserved